Bookbot

The Merck Druggernaut

Ocena książki

Parametry

  • 304 strony
  • 11 godzin czytania

Więcej o książce

An in-depth look at big pharma's flagship company, this book takes readers inside Merck, the world's second most profitable drug company and maker of the bestselling drug, Prilosec. Consistently recognized by Fortune magazine as one of the Most Admired Companies, Merck faces challenges in maintaining its reputation for ethical practices amid declining profits, falling stock prices, and questionable accounting. Author Fran Hawthorne, a leading journalist in healthcare, provides a thorough examination of this business paragon, offering crucial insights into the competitive pharmaceutical landscape. The narrative appeals to both the business community and healthcare advocates by addressing vital issues in medicine today. More than just a compelling success story in a challenging industry, it thoughtfully explores significant contemporary issues and their connections to the business world. Fran Hawthorne, based in New York, serves as the Assistant Managing Editor at Crain's New York Business and has over twenty years of experience covering business for prominent publications, focusing on healthcare and pharmaceuticals. At Crain's, she leads the publication of multiple special healthcare issues each year.

Zakup książki

The Merck Druggernaut, Fran Hawthorne

Język
Rok wydania
2003
Oprawa
(twarda)
Jak tylko się pojawi, wyślemy Ci wiadomość e-mail.

Metody płatności

3,6
Bardzo dobra
5 Ocena

Brakuje nam tutaj Twojej recenzji.

Tytuł
The Merck Druggernaut
Język
angielski
Wydawca
WILEY
Rok wydania
2003
Oprawa
twarda
Liczba stron
304
ISBN10
0471228788
ISBN13
9780471228783
Seria
Tagi
Ocena
3,6 z 5
Opis
An in-depth look at big pharma's flagship company, this book takes readers inside Merck, the world's second most profitable drug company and maker of the bestselling drug, Prilosec. Consistently recognized by Fortune magazine as one of the Most Admired Companies, Merck faces challenges in maintaining its reputation for ethical practices amid declining profits, falling stock prices, and questionable accounting. Author Fran Hawthorne, a leading journalist in healthcare, provides a thorough examination of this business paragon, offering crucial insights into the competitive pharmaceutical landscape. The narrative appeals to both the business community and healthcare advocates by addressing vital issues in medicine today. More than just a compelling success story in a challenging industry, it thoughtfully explores significant contemporary issues and their connections to the business world. Fran Hawthorne, based in New York, serves as the Assistant Managing Editor at Crain's New York Business and has over twenty years of experience covering business for prominent publications, focusing on healthcare and pharmaceuticals. At Crain's, she leads the publication of multiple special healthcare issues each year.